Cardiol Therapeutics Inc.
CRDL
$1.17
$0.0857.87%
09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 18.00M | 14.17M | 12.60M | 11.53M | 11.16M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 28.16M | 23.50M | 22.54M | 22.07M | 22.87M |
Operating Income | -28.16M | -23.50M | -22.54M | -22.07M | -22.87M |
Income Before Tax | -26.57M | -21.66M | -22.41M | -20.84M | -20.76M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -26.57 | -21.66 | -22.41 | -20.84 | -20.76 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -26.57M | -21.66M | -22.41M | -20.84M | -20.76M |
EBIT | -28.16M | -23.50M | -22.54M | -22.07M | -22.87M |
EBITDA | -28.03M | -23.35M | -22.38M | -21.89M | -22.72M |
EPS Basic | -0.39 | -0.33 | -0.34 | -0.32 | -0.32 |
Normalized Basic EPS | -0.24 | -0.20 | -0.21 | -0.20 | -0.20 |
EPS Diluted | -0.39 | -0.33 | -0.34 | -0.32 | -0.32 |
Normalized Diluted EPS | -0.24 | -0.20 | -0.21 | -0.20 | -0.20 |
Average Basic Shares Outstanding | 271.01M | 265.66M | 261.02M | 257.85M | 256.51M |
Average Diluted Shares Outstanding | 271.01M | 265.66M | 261.02M | 257.85M | 256.51M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |